Lexeo Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Lexeo Therapeutics, Inc. (LXEO) reported Basic Shares Outstanding (Weighted Average) of 85.63 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- Lexeo Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 85.63M shares, a 96.51% increase year-over-year.
- Lexeo Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 81.18M shares, a 145.16% increase year-over-year.
- Lexeo Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 76.61M shares, a 131.54% increase year-over-year.
- Lexeo Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 60.98M shares, a 84.44% increase year-over-year.
- Lexeo Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 53.65M shares, a 68.76% increase from fiscal 2024.
- Lexeo Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 31.79M shares, a 493.67% increase from fiscal 2023.
- Lexeo Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 5.35M shares, a 228.42% increase from fiscal 2022.
- Lexeo Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 1.63M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 85.63M shares 10-Q · filed 2026-08-12 | 83.42M shares 10-Q · filed 2026-08-12 | 81.14M shares derived: average of 3 quarters · filed 2026-08-12 | 76.10M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 81.18M shares 10-Q · filed 2026-05-11 | 78.90M shares derived: average of 2 quarters · filed 2026-05-11 | 72.92M shares derived: average of 3 quarters · filed 2026-05-11 | 65.59M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | 76.61M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 68.79M shares derived: average of 2 quarters · filed 2026-03-30 | 60.39M shares derived: average of 3 quarters · filed 2026-08-12 | 53.65M shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 60.98M shares 10-Q · filed 2025-11-05 | 52.28M shares derived: average of 2 quarters · filed 2026-08-12 | 45.99M shares 10-Q · filed 2025-11-05 | 42.69M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | 43.57M shares 10-Q · filed 2026-08-12 | 38.37M shares 10-Q · filed 2026-08-12 | 36.59M shares derived: average of 3 quarters · filed 2026-08-12 | 35.71M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | 33.11M shares 10-Q · filed 2026-05-11 | 33.10M shares derived: average of 2 quarters · filed 2026-05-11 | 33.09M shares derived: average of 3 quarters · filed 2026-05-11 | 33.07M shares derived: average of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | 33.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 33.07M shares derived: average of 2 quarters · filed 2026-03-30 | 33.05M shares derived: average of 3 quarters · filed 2026-03-30 | 31.79M shares 10-K · filed 2026-03-30 |
| 2024-09-30 | 33.06M shares 10-Q · filed 2025-11-05 | 33.03M shares derived: average of 2 quarters · filed 2025-11-05 | 31.35M shares 10-Q · filed 2025-11-05 | 27.65M shares derived: average of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | 33.00M shares 10-Q · filed 2025-08-14 | 30.49M shares 10-Q · filed 2025-08-14 | 25.85M shares derived: average of 3 quarters · filed 2025-08-14 | 19.79M shares derived: average of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | 27.98M shares 10-Q · filed 2025-05-12 | 22.27M shares derived: average of 2 quarters · filed 2025-05-12 | 15.39M shares derived: average of 3 quarters · filed 2025-05-12 | 11.95M shares derived: average of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | 16.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | 9.09M shares derived: average of 2 quarters · filed 2025-03-24 | 6.60M shares derived: average of 3 quarters · filed 2025-03-24 | 5.35M shares 10-K · filed 2025-03-24 |
| 2023-09-30 | 1.63M shares 10-Q · filed 2024-11-13 | 1.62M shares derived: average of 2 quarters · filed 2024-11-13 | 1.62M shares 10-Q · filed 2024-11-13 | 1.63M shares derived: average of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | 1.62M shares 10-Q · filed 2024-08-12 | 1.62M shares 10-Q · filed 2024-08-12 | 1.62M shares derived: average of 3 quarters · filed 2024-08-12 | 1.63M shares derived: average of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | 1.61M shares 10-Q · filed 2024-05-09 | 1.63M shares derived: average of 2 quarters · filed 2024-05-09 | 1.63M shares derived: average of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | 1.64M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 1.64M shares derived: average of 2 quarters · filed 2024-03-11 | 1.63M shares 10-K · filed 2024-03-11 | |
| 2022-09-30 | 1.64M shares 10-Q · filed 2023-12-11 | 1.63M shares 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |